Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model

High-throughput target discovery confronts the biopharmaceutical industry with a plethora of target candidates. The validation of these candidates in disease-specific animal models often lacks the required throughput. Here, we discuss perspectives and limitations of a novel engineered three-dimensio...

Full description

Saved in:
Bibliographic Details
Published in:Drug Discovery Today 2002-04, Vol.7 (7), p.419-425
Main Authors: Navé, Barbara T, Becker, Michael, Roenicke, Volker, Henkel, Thomas
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Cardiovascular Agents - pharmacology
Cardiovascular system
Drug Evaluation, Preclinical - methods
Heart - anatomy & histology
Heart - drug effects
Humans
Medical sciences
Miscellaneous
Models, Anatomic
Myocardium - cytology
Pharmacology. Drug treatments
Reproducibility of Results
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High-throughput target discovery confronts the biopharmaceutical industry with a plethora of target candidates. The validation of these candidates in disease-specific animal models often lacks the required throughput. Here, we discuss perspectives and limitations of a novel engineered three-dimensional cardiac tissue, which enables the influence of gene and drug intervention to be monitored on a cellular and molecular level under physiological conditions in sufficient throughput. The model is an extremely helpful filter to prioritize multiple development candidates before moving a project into large animal models with higher predictivity.
ISSN:1359-6446
1878-5832
DOI:10.1016/S1359-6446(02)02212-2